Treatment of recurrent iridochoroiditis horses

 

(57) Abstract:

The invention relates to agriculture, in particular animal health, and can be used to treat horses, patients relapsing iridocyclitis. Treatment of recurrent iridochoroiditis by assigning diet and the introduction of subconjuctival medicines containing (in wt.%):

Atropine sulfate 0,02 - 0,1

Dexamethasone 0,6-1,0

Gentamicin sulfate 0,6-1,0

Novocaine 0,3-0,5

Water Rest

moreover, the introduction is carried out 1 time a day at intervals of 4-5 days, additionally, instillaciei enter 0,8-1,0% solution mezatona and 0.02-0.05% solution of ciprofloxacin based 1-2 drops 2-3 times a day for 14 -21 days and per os 3-6 mg of acetylsalicylic acid per 1 kg of weight of the animal within 10-14 days. The method improves the efficiency of treatment up to 80-100%.

The present invention relates to the field of agriculture, in particular animal health, and can be used in animal husbandry for the treatment of horses, patients relapsing iridocyclitis.

There is a method of treatment of recurrent iridochoroiditis the date 1985, pp. 222-227). However, the method is not effective enough.

The technical effect of the invention is to increase the efficiency of the method by reducing relapses.

The technical result is achieved in a method of treatment of recurrent iridochoroiditis by diet and the introduction of subconjuctival atropine sulfate and water that subconjuctival impose additional dexamethasone gentamicin sulfate and novocaine, in the following ratio of components, wt.%:

Atropine sulfate 0,02-0,1

Dexamethasone 0,6-1,0

Gentamicin sulfate 0,6-1,0

Novocaine 0,3-0,5

Water the Rest

moreover, the introduction is carried out 1 time a day at intervals of 4-5 days, additionally, instillaciei enter 0,8-1,0% solution mezatona and 0.02-0.05% solution of ciprofloxacin based 1-2 drops 2-3 times a day for 14-21 days and per os 3-6 mg of acetylsalicylic acid per 1 kg of weight of the animal within 10-14 days.

Acetylsalicylic acid, salicylic ester acetic acid (Reference “Medicines used in medical practice in the USSR, M.: Medicine, S. 38) - has antipyretic, analgesic and anti-inflammatory effect.

Ciprofloxacin - 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7(1-piperazinil)-3-quinoline carboxylic acid hydrochloride monohydrate - (registration number P-8-242 No. 008395) - antimicrobial drug (Handbook of General practitioners./Ed. by Acad. THE RAMS N. R. Maleeva, T. 1, M, 2002, S. 84-87).

Dexamethasone - 9-fluoro-16-methylprednisolone (ibid, S. 105) - has anti-inflammatory and antiallergic effect. Inhibits the release of ACTH.

Gentamicin sulfate is an antibiotic produced Mecromonospora purpurea or Echinospora (ibid, p. 85).

Novocaine (ibid, S. 251) - -diethyl ether, para-aminobenzoic acid hydrochloride, used as a local anesthetic agent.

Mezaton (ibid, 212 S.) - 1-(meta-oxyphenyl)-2-methylaminoethanol hydrochloride, used as adrenomimeticescoe tool expands the pupil and lowers intraocular pressure.

In the patent and scientific literature is not well-known technical solutions containing elements similar stated, i.e., the proposal meets the criterion of “novelty”.

We first established that the application of atropine sulfate, dexamethasone, gentamicin, novocaine in a certain ratio together with mezatona Policom, i.e., the proposal meets the criterion of “inventive level”.

All ingredients are produced by the domestic industry, i.e., the sentence “industrially applicable”.

The invention is illustrated in the following examples.

Example 1. First prepare the drug required to subconjuctival introduction. To 0.02 g of atropine sulfate add 0.6 g of dexamethasone, 0.6 g of gentamicin sulfate, 0.3 g of novocaine and 98,48 g of water, i.e., have the structure 1 in the following ratio, wt.%:

Atropine sulfate 0,02

Dexamethasone 0,6

Gentamicin sulfate 0,6

Novocaine 0,3

Water the Rest

To 0.1 g of atropine sulfate add 1.0 g of dexamethasone, 1.0 g of gentamicin sulfate, 0.5 g of novocaine and of 97.4 g of water, i.e., get part 2 in the following ratio, wt.%:

Atropine sulfate is 0.1

Dexamethasone 1,0

Gentamicin sulfate 1,0

Novocaine 0,5

Water the Rest

To 0.05 g of atropine sulfate add 0.8 g of dexamethasone, 0.8 g of gentamicin sulfate, 0.4 g of novocaine and 97,95 g of water, i.e., the receiving part 3 in the following ratio, wt.%:

Water the Rest

Pick four groups of horses, patients relapsing iridocyclitis on the principle of analogues for 10 animals in each group. The first group in the eyes of the animals subconjuctival have introduced the structure 1, the second group - part 2, the third group - part 3. The fourth group served as control animals were injected as in the known method, a 0.1% aqueous solution of atropine sulfate. Subconjuctival injection of compounds 1-3 was performed 1 time per day at intervals of 4 days within 14 days against the backdrop of diets. 0.8% solution mezatona and 0.02% solution of ciprofloxacin was administered by instillaciei (dripping in conductively bag) 1 drop 2 times a day for 14 days. Animals were also given per os 6 mg of acetylsalicylic acid per kg weight of the animal within 14 days. As a result, in the first three groups completely disappeared acute clinical signs of disease (keratitis and iridocyclitis) in 28 animals (93%), recurrence was found in only one animal in the first group. In a fourth control group acute clinical signs disappeared only two animals (20%), and relapse occurred in all horses (100%).

Example 2. Use the compounds 1-3, obtained in accordance with example 1. Pick four groups the first group in the eyes of the animals subconjuctival have introduced the structure 1, the second group - part 2, the third group - part 3. The fourth group served as control animals were injected as in the known method, a 0.1% aqueous solution of atropine sulfate. Subconjuctival injection of compounds 1-3 was performed 1 time per day with an interval of 5 days within 21 days against the backdrop of diets. 1,0% solution mezatona and 0.05% solution of ciprofloxacin was administered by instillaciei 2 drops 3 times a day for 21 days. The diet consisted, as in the known method, the withdrawal from the diet of oats. Animals were also given per os 3 mg of acetylsalicylic acid per 1 kg of weight of the animal within 10 days. The result: in the first third groups completely disappeared acute clinical signs of disease (keratitis and iridocyclitis) in 29 animals (97%), recurrences were found in one animal (3%) for the whole observation period (100 days). In a fourth control group acute clinical signs disappeared, only one horse (10%), and relapse occurred in all animals (100%).

Example 3. Use the compounds 1-3, obtained in accordance with example 1. Pick four groups of horses, patients relapsing iridocyclitis on the principle of analogues for 10 animals in each group. The first group in the eyes of the animals subconjuctival has introduced sostak and in a known way, 0.1% aqueous solution of atropine sulfate. Subconjuctival injection of compounds 1-3 was performed 1 time per day every 5 days for 18 days on the background diet. 0.9% solution mezatona and 0.035% solution of ciprofloxacin was administered by instillaciei 2 drops 3 times a day for 18 days. The diet consisted, as in the known method, the withdrawal from the diet of oats. Animals were also given per os 3 mg of acetylsalicylic acid per 1 kg of weight of the animal within 10 days. The result: in the first third groups completely disappeared acute clinical signs of disease (keratitis and iridocyclitis) in 28 animals (93%), recurrence was found neither of the two animals (7%) for the whole observation period (100 days). In a fourth control group acute clinical signs disappeared, only one horse (10%), and relapse occurred in all animals (100%).

Thus, the proposed method for the treatment of recurrent iridochoroiditis allows 93-97% reduction in the recurrence of the disease, as well as 80-90% increase in the recovery of animals from recurrent iridochoroiditis.

Treatment of recurrent iridochoroiditis by subconjuctival introduction on the background diet medicines containing atropine sulfate and the and the novocaine in the following ratio of components, wt.%:

Atropine sulfate 0,02-0,1

Dexamethasone 0,6-1,0

Gentamicin sulfate 0,6-1,0

Novocaine 0,3-0,5

Water the Rest

moreover, the introduction is carried out 1 time a day at intervals of 4-5 days, additionally, the instillation enter 0,8-1,0% solution mezatona and 0.02-0.05% solution of ciprofloxacin based 1-2 drops 2-3 times a day for 14 -21 days and per os 3-6 mg of acetylsalicylic acid per 1 kg of weight of the animal within 10-14 days.

 

Same patents:
The invention relates to agriculture, in particular animal health, and can be used to treat horses, patients relapsing iridocyclitis

The invention relates to the field of medicine and relates to a composition for topical application, reducing intraocular pressure, comprising the antagonist of angiotensin II, boric acid and ethylenediaminetetraacetic acid
The invention relates to medicine, in particular to ophthalmology, and can be used in the treatment pseudophoenix diseases of the orbit

The invention relates to medicine, in particular to ophthalmology, and can be used as ophthalmic medicines for the treatment of diseases and injuries of the cornea
The invention relates to medicine, in particular to ophthalmology, and can be used for the treatment of patients with diabetic retinopathy
The invention relates to medicine, in particular to ophthalmology, and can be used for the treatment of postinflammatory bullous keratopathy

The invention relates to medicine, namely to ophthalmology, and for the treatment of edematous maculopathy
The invention relates to medicine, namely to ophthalmology, and for the prevention of postoperative complications antiglaucomatous surgery
The invention relates to medicine, namely to ophthalmology, and for the treatment of endocrine ophthalmopathy

The invention relates to medicine, to the agent for the prevention or treatment of diseases associated with excessive proliferation of the epithelial pigment cells of the retina, such as proliferative vitreoretinopathy, and includes as the active ingredient N-(3,4-dimethoxycinnamoyl) Anthranilic acid of formula I or its pharmaceutically acceptable salt
The invention relates to agriculture, in particular animal health, and can be used to treat horses, patients relapsing iridocyclitis
The invention relates to veterinary

The invention relates to the field of veterinary medicine

The invention relates to the field of dentistry

The invention relates to medicine, namely to experimental pharmacology and cardiology

The invention relates to medicine, specifically to antientropy using antisense oligonucleotides

The invention relates to the field of clinical medicine - Phthisiology and can be used in the treatment of patients with caseous pneumonia to reduce the severity of the intoxication syndrome, normalization of blood system, withdrawal side effects from anti-TB therapy

The invention relates to the compound of formula (I)

where R1represents (i) R3-Z3or (ii) R3-L3-Ar1-L4-Z3-; R2is hydrogen; R3represents alkyl; aryl, optionally substituted by one or two substituents from halogen and C1-4-alkyl; arylalkyl; R5is hydrogen; R7and R7arepresent hydrogen; R8is hydrogen; R9is alkyl; optionally substituted with halogen aryl; heteroaryl containing up to 2 heteroatoms selected from nitrogen atoms and oxygen, or alkyl substituted by aryl or heteroaryl; AND1is unsubstituted C1-3-alkylenes communication with the linear chain; Ar1is arisen, which may be optionally substituted C1-4-alkoxy; or heteroaryl containing up to 2 heteroatoms selected from nitrogen atoms and oxygen; L1is alkylenes communication, which is optionally substituted by-N(R8)-C(=O)-R9, -N(R8)-C(=O)-OR9, -N(R8)-SO2-R9; L3is-NR5-C(=Z)-NR5-, -Z-, -NR5-, -NR5-C(=O)-O-, or-O-C(=O)-NR5-; L4); Z3represents C(=O) or SO2; Y is carboxy; provided that when R1is R3or R3-C(=O) R3can't imagine alkyl; or its corresponding N-oxide or ester, which can be converted in vivo by the action of metabolism in primary molecule, or a pharmaceutically acceptable salt of such a compound, or its N-oxide or its ether complex
Up!